Sheldon Whitehouse has built a career out of demanding transparency from everyone else. The Rhode Island senator chairs no shortage of oversight terrain across the Environment and Public Works, Finance, and Judiciary committees. He votes to protect CFPB rules. He votes to block EPA rollbacks. He votes to push troops out of Iran without congressional authorization. The man is busy. He is also, per public disclosure filings, selling stocks at a pretty consistent clip, posting a mean 30-day alpha of negative 4.7 percent across 36 scored trades. Eleven of those trades beat the market. Twenty-five did not. That's the record. The filings are public. Readers get to bring their own opinion.
What He's Selling Right Now
Four disclosed trades in the last 90 days. All sales. Not a single buy.
The full disclosure record at Blind Trust shows the sequence: a PepsiCo sale on March 30 in the K-5K range, a JPMorgan Chase sale on April 13 in the 5K-$50K range, an Oracle sale on May 7 in the 5K-$50K range, and then the headliner: a sale of DA (Dairy Farmers of America's parent, Danone's U.S.-traded shares) on May 8 in the 00K-$250K range. That last one is the biggest disclosed trade of the quarter by a wide margin.
Taken together, the disclosed range on those four transactions runs from roughly 31,000 to $365,000. The upper bound clears $365K in stock moved out the door in 90 days. For a senator who has made corporate accountability his calling card, the portfolio is active.
The Alpha Record, Unvarnished
Here is the stat line across 36 scored trades: 11 positive, 25 negative, mean 30-day alpha of minus 4.7 percent against the S&P 500. That's the full sample.
The worst trades in the record are genuinely bad. The PepsiCo sale filed March 30, 2026 (the same one in the current 90-day window) logged a 30-day alpha of negative 14.9 percent. A Kenvue sale in August 2025 hit negative 23.0 percent. An Nvidia sale in January 2025 came in at negative 22.3 percent. On the Nvidia trade, a committee-overlap flag applies: Whitehouse sits on committees with technology jurisdiction, and the position was in the 5K-$50K range. The 30-day alpha was negative 22.3 percent. Selling Nvidia badly while sitting on a tech-adjacent committee is its own kind of commentary.
The best trades in the record are more interesting, and some of them carry overlap flags that are worth naming directly.
Where the Overlap Flags Live
Blind Trust cross-references committee jurisdiction against disclosed trades. Two tickers show up on the committee-overlap list with positive alpha.
First: UnitedHealth Group. Whitehouse sits on the Senate Finance Committee's Health Care subcommittee. He sold UnitedHealth shares on September 4, 2025, in the 5K-$50K range. Thirty-day alpha on that trade: plus 6.5 percent. He sold UnitedHealth again on August 28, 2025, also in the 5K-$50K range, logging a 30-day alpha of plus 2.6 percent. Two UnitedHealth sales in the same month, both positive alpha, both with a committee-overlap flag on a senator who oversees healthcare legislation. The timing is the thing.
Second: Mastercard. Whitehouse's Finance Committee assignment includes financial services jurisdiction. He sold Mastercard on February 23, 2026, in the K-5K range. Thirty-day alpha: plus 4.4 percent. A small position, but the overlap flag is there.
No vote-trade overlaps are flagged in this data set for the current 90-day window. The committee-overlap trades above come from the broader scored sample. The record of what was sold and when is public. The committee assignments are public. The math is yours to run.
What He's Been Voting On
May 13 was a busy floor day. Whitehouse voted Yea on three separate motions to proceed on CFPB-related congressional disapproval resolutions: one covering the rollback of medical debt collection rules, one covering overdraft opt-in practices, and one covering servicemember protection examinations. All three motions failed. He was on the losing side of all three, voting to preserve the CFPB rules the Republican majority moved to dismantle.
The Finance Committee's jurisdiction covers financial regulation. JPMorgan Chase, which Whitehouse sold on April 13 in the 5K-$50K range, is precisely the kind of institution these CFPB rules govern. The JPM sale predates the May 13 votes by about a month. No vote-trade overlap is flagged here because the timing gap is wide. Still: a Finance Committee member selling JPMorgan shares ahead of a floor fight over financial consumer protection rules is a fact the public record contains.
On June 3, he voted Yea on a motion to proceed on a resolution disapproving the EPA's rollback of hazardous air pollutant standards for coal and oil-fired power plants. That motion also failed. Whitehouse sits on the full Environment and Public Works Committee plus its Clean Air, Climate, and Nuclear Innovation and Safety subcommittee. No trades in the current 90-day window touch energy or utility tickers directly. The vote is a vote.
On May 19, the Senate voted to discharge S.J.Res. 185, the joint resolution directing removal of U.S. Forces from hostilities against Iran without congressional authorization. Whitehouse voted Yea. That motion succeeded. It's one of the few recent votes where he ended up on the winning side of a roll call. The Oracle sale cleared two days before that vote, on May 7. Oracle is a technology and cloud infrastructure company with significant federal government contracts. No committee-overlap flag is applied to that ticker in the current data. The sale and the vote are two separate facts sitting near each other on the calendar.
The Accountability Senator's Portfolio Problem
Whitehouse is not a wallflower on these issues. He has been one of the more consistent Democratic voices demanding corporate accountability, pushing CFPB enforcement, and calling for tougher environmental standards. The Bluesky conversation around him this week includes mentions of pressure campaigns on financial regulation alongside fellow senators.
Members are required to disclose stock trades within 45 days. They are not required to divest, recuse, abstain, or explain the timing. That's the rule. Yes, really.
It's that a senator who has made financial accountability a marquee issue, who sits on the Finance Committee and votes repeatedly on financial consumer protection, has a portfolio that's actively trading financial sector names. It's the largest U.S. Bank by assets, and its regulatory environment is shaped in part by the committee Whitehouse sits on.
Across 36 scored trades, 25 lost to the market. The mean alpha is negative 4.7 percent. The record does not suggest unusual foresight. But the committee-overlap trades that did beat the market, specifically the two UnitedHealth sales in August and September 2025, logged plus 6.5 percent and plus 2.6 percent alpha respectively, and both carry the healthcare committee flag. That's two data points, not a pattern. It's also two data points the public record contains.
The Bottom Line
Four sales in 90 days. A disclosed range topping out near $365,000. A 36-trade sample with 25 losers and a mean alpha of negative 4.7 percent. Two committee-overlap trades in the full record that beat the market, both in healthcare, both involving UnitedHealth. A JPMorgan sale a month before a floor fight over financial consumer protection. An Oracle sale days before an Iran-related vote.
The Blind Trust disclosure record has the full trade history. The Senate roll-call database has the full vote history. The committee assignments are published by the Senate. Every piece of this is public.
Whitehouse has positioned himself as the person in the room who asks uncomfortable questions about who benefits. The receipts are public. Make of them what you make of them.